122 related articles for article (PubMed ID: 12018644)
1. Recombinant human erythropoietin (rHuEPO): more than just the correction of uremic anemia.
Buemi M; Aloisi C; Cavallaro E; Corica F; Floccari F; Grasso G; Lasco A; Pettinato G; Ruello A; Sturiale A; Frisina N
J Nephrol; 2002; 15(2):97-103. PubMed ID: 12018644
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin and chronic lymphocytic leukemia.
Mauro FR; Gentile M; Foa R
Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212
[TBL] [Abstract][Full Text] [Related]
3. EPO's alter ego: erythropoietin has multiple actions.
Lappin TR; Maxwell AP; Johnston PG
Stem Cells; 2002; 20(6):485-92. PubMed ID: 12456956
[TBL] [Abstract][Full Text] [Related]
4. Perturbation of autocrine/paracrine loops of burst-forming units of erythroid-derived cells in rHuEPO-hyporesponsive hemodialysis patients.
Nakao K; Wada J; Ota K; Ichikawa H; Akagi S; Okamoto A; Hida K; Nagake Y; Makino H
Am J Kidney Dis; 2003 Mar; 41(3):624-36. PubMed ID: 12612986
[TBL] [Abstract][Full Text] [Related]
5. From the oxygen to the organ protection: erythropoietin as protagonist in internal medicine.
Buemi M; Nostro L; Romeo A; Giacobbe MS; Aloisi C; Sturiale A; Bolignano D; Allegra A; Grasso G; Frisina N
Cardiovasc Hematol Agents Med Chem; 2006 Oct; 4(4):299-311. PubMed ID: 17073607
[TBL] [Abstract][Full Text] [Related]
6. The pleiotropic effects of erythropoietin in the central nervous system.
Buemi M; Cavallaro E; Floccari F; Sturiale A; Aloisi C; Trimarchi M; Corica F; Frisina N
J Neuropathol Exp Neurol; 2003 Mar; 62(3):228-36. PubMed ID: 12638727
[TBL] [Abstract][Full Text] [Related]
7. To give or not to give recombinant EPO to anemia endangered cancer patients.
Sulkowska M; Wincewicz A; Chabowska A; Kanczuga-Koda L; Szymanska M; Koda M; Witkowska E; Sulkowski S
Prague Med Rep; 2006; 107(3):281-9. PubMed ID: 17385400
[TBL] [Abstract][Full Text] [Related]
8. The biology and clinical applications of recombinant erythropoietin.
Spivak JL
Semin Oncol; 1998 Jun; 25(3 Suppl 7):7-11. PubMed ID: 9671323
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin and the hypoxic brain.
Marti HH
J Exp Biol; 2004 Aug; 207(Pt 18):3233-42. PubMed ID: 15299044
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic skin ulcers in individuals with anemia of chronic disease using recombinant human erythropoietin (EPO): a review of four cases.
Keast DH; Fraser C
Ostomy Wound Manage; 2004 Oct; 50(10):64-70. PubMed ID: 15509883
[TBL] [Abstract][Full Text] [Related]
11. The interaction between heart failure and other heart diseases, renal failure, and anemia.
Silverberg DS; Wexler D; Iaina A; Schwartz D
Semin Nephrol; 2006 Jul; 26(4):296-306. PubMed ID: 16949468
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies.
Mittelman M; Zeidman A; Kanter P; Katz O; Oster H; Rund D; Neumann D
Eur J Haematol; 2004 Mar; 72(3):155-65. PubMed ID: 14962233
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin in cancer: the new face of an old friend.
Megalakaki C
J BUON; 2008; 13(1):7-16. PubMed ID: 18404780
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human erythropoietin improves angiogenesis and wound healing in experimental burn wounds.
Galeano M; Altavilla D; Bitto A; Minutoli L; Calò M; Lo Cascio P; Polito F; Giugliano G; Squadrito G; Mioni C; Giuliani D; Venuti FS; Squadrito F
Crit Care Med; 2006 Apr; 34(4):1139-46. PubMed ID: 16484928
[TBL] [Abstract][Full Text] [Related]
15. The erythropoietin receptor and its expression in tumor cells and other tissues.
Farrell F; Lee A
Oncologist; 2004; 9 Suppl 5():18-30. PubMed ID: 15591419
[TBL] [Abstract][Full Text] [Related]
16. Activation and inhibition of the erythropoietin receptor by a membrane-anchored erythropoietin.
Negre O; Fusil F; Henri A; Villette JM; Leboulch P; Beuzard Y; Payen E
Exp Hematol; 2008 Apr; 36(4):412-23. PubMed ID: 18295963
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human erythropoietin prevents lipopolysaccharide-induced vascular hyporeactivity in the rat.
di Villa Bianca Rd; Sorrentino R; Mitidieri E; Marzocco S; Autore G; Thiemermann C; Pinto A; Sorrentino R
Shock; 2009 May; 31(5):529-34. PubMed ID: 18838949
[TBL] [Abstract][Full Text] [Related]
18. [Erythropoietin: indications and measurement].
Klein E; Georges A; Brossaud J; Bosredon Kd; Bordenave L; Corcuff JB
Ann Biol Clin (Paris); 2009; 67(5):505-15. PubMed ID: 19789122
[TBL] [Abstract][Full Text] [Related]
19. [Erythropoietin: pleiotropic actions].
Buemi M; Donato V; Bolignano D
Recenti Prog Med; 2010 Jun; 101(6):253-67. PubMed ID: 20672574
[TBL] [Abstract][Full Text] [Related]
20. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.
Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY;
J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
